WO1997020539A1 - Preparation cosmetique - Google Patents

Preparation cosmetique Download PDF

Info

Publication number
WO1997020539A1
WO1997020539A1 PCT/JP1996/003571 JP9603571W WO9720539A1 WO 1997020539 A1 WO1997020539 A1 WO 1997020539A1 JP 9603571 W JP9603571 W JP 9603571W WO 9720539 A1 WO9720539 A1 WO 9720539A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
sod
zinc
manganese
bacteria
Prior art date
Application number
PCT/JP1996/003571
Other languages
English (en)
Japanese (ja)
Inventor
Keiichiro Okabe
Shouichiro Kondo
Aya Katsuyama
Original Assignee
Kabushiki Kaisya Advance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabushiki Kaisya Advance filed Critical Kabushiki Kaisya Advance
Publication of WO1997020539A1 publication Critical patent/WO1997020539A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof

Definitions

  • the present invention relates to a cosmetic composition, and more specifically, to maintain and enhance a healthy flora resident in the skin, and to provide a suboxyxide dismutase (SOD) -like active substance secreted by the bacteria resident in the skin.
  • SOD suboxyxide dismutase
  • SOD derived from natural products purified from animals, plants, and microorganisms, or SOD derived from DNA recombinants are not suitable for quality control, such as storage stability in pharmaceuticals, from the viewpoint of production cost and storage stability in pharmaceuticals. Had problems.
  • the purpose of the present invention is to grow most of the SOD or SOD-like active substance on the skin of healthy people instead of directly blending it into cosmetics so that the SOD or SOD-like active substance can always be stably expressed on the skin It.
  • a cosmetic composition comprising at least one of a metal ion, a metal salt and a metal substance.
  • the action of enhancing the growth of Staphylococcus epidermides, the most aerobic bacterium of the useful skin flora, and the function of producing and secreting Superoxide jism Cosmetic composition containing trace amounts of at least one of manganese and zinc, which are metal ions, and salts thereof, which have an effect of enhancing SOD-like active substances Is provided.
  • Figure 1 shows the effect of metal ions (zinc and manganese) on the development of Staphylococcus epidermides.
  • Figure 2 shows the effect of metal ions (zinc and manganese) on the growth of Staphylococcus aureus.
  • the present invention has conducted intensive studies to increase the extracellular SOD-like specific activity of Staphylococcus' epidermides, and to reduce the metal ions manganese and zinc even in poor nutrient media.
  • the present inventors have found that by adding the same, the same bacterium can be grown in a short time and the extracellular SOD-like active substance can be maintained for a long period of time, and the present invention has been accomplished.
  • the present invention is a cosmetic containing a substance capable of growing Staphylococcus epidermides resident on the skin in a short period of time and increasing the extracellular SOD-like specific activity.
  • this cosmetic is a highly stable and safe cosmetic that achieves skin conditioning by normalizing the skin flora and enhancing the activity of its extracellular secretory SOD-like active substance.
  • the Staph I Loco Tsu dregs-E Biderumi death is established growth on the surface of the skin due to the high antioxidant capacity, and secrete the SOD-like active substances in the cells outside the body, the 0 2 on the skin caused Ri by such as on the results of ultraviolet rays It is thought to play a role in eliminating skin injuries by erasing, increasing skin health, and preventing other bacterial infections. In fact, skin with injuries such as atopic dermatitis (rough skin) or dry skin loses the balance of the bacterial bacterial flora and belongs to the genus Staphylococcus aureus. Harmful bacteria are found at a high rate. S.
  • phylococcus as the dominant bacterium ⁇ Epidermides inhibits the growth of the above harmful bacteria, so that a slight skin injury can cause selective growth of Staphylococcus epidermides.
  • Providing a cosmetic composition that can be used to reduce the number of pathogenic bacteria and improve skin damage can be expected.
  • metal ions for example, Mn, Zn2 +
  • metal salts for example, manganese chloride, zinc chloride, zinc oxide, zinc stearate, paraffin
  • the cosmetic according to the second aspect of the present invention has an effect of enhancing the growth of Staphylococcus epidermides, the most aerobic bacterium of the useful skin flora, and producing and secreting the cells.
  • One of the metal ions manganese and zinc or their salts (eg, manganese chloride and zinc oxide) that have the effect of enhancing superoxide 'dismutase (SOD) -like active substances In trace amounts.
  • the manganese ion preferably has a concentration in the range of 0.1 to 100 mM, more preferably 0.1 to 10 mM.
  • the zinc ion preferably has a concentration in the range of 0.01 to 5 mM, and more preferably 0.1 to 1 mM.
  • the microorganism used to prove the effectiveness of the present invention was Staphylococcus epider, a representative resident bacterium inhabiting the skin of healthy humans, as used in the following examples.
  • a force that is a mide or a skin Staphylococcus ⁇ P. aureus is a representative of skin harmful bacteria.
  • the bacterium used to carry out the present invention can be used irrespective of any bacterial species and strains, including those that can pass through the skin.
  • the minimum growth medium used in the present invention is defined as a medium to which a minimum concentration of metal capable of growing bacteria is added.
  • the method of culturing bacteria used to prove the effectiveness of the present invention is as follows: using the above strains and medium, the bacteria are grown under aerobic conditions at 37 ° C under a rotary culture (120 rpm). ).
  • the sample preparation method used to prove the effectiveness of the present invention is as follows. First, bacteria sufficiently grown in the above medium were separated into bacterial cells and culture supernatant at 4 ° C for 10 minutes using a cooling high-speed centrifuge. Subsequently, the SOD activity of the culture supernatant was measured and concentrated as follows. Add cold acetate to the culture supernatant to a final concentration of 75%, leave it in a freezer at 120 ° C, separate and collect the formed precipitate with a cooling centrifuge, and dissolve in a small amount of purified water Then, freeze drying was performed to obtain an acetone powder sample. The powder was dissolved in purified water and used as an extracellular secretory component sample.
  • NBT Nitrole tetrazolium
  • SOD activity is determined from this inhibition rate. Using this method, SOD-like active substances secreted outside the cells can be measured with high sensitivity by acetonitrile concentration treatment of the culture supernatant sample.
  • the basal medium used in the series of experiments was Davis's medium (sinium sodium hydrogen phosphate decahydrate, 8 g; potassium dihydrogen phosphate, 2 g; sodium citrate, 0.5 g). g; magnesium sulfate heptahydrate, 0.1 g; ammonium sulfate, 1 g; glucose, 0.5 g / liter of distilled water (pH 7)) plus 0.1% of yeast extract and 1% of carbonated calcium was used.
  • the inoculum was set at 1 ⁇ 10 5 cells / ml, and the culture was performed in a thermostat at 37 ° C.
  • the metals used in the experiments were copper sulfate, zinc sulfate, manganese chloride, zinc oxide, and ferrous sulfate.
  • the concentrations were 100 / M, 1 mM, and 10 mM, respectively, and were added before the start of culture. After culturing for 24 hours, the culture solution was applied to a standard agar plate, and the number of viable cells was counted by a standard method. The results are shown in Table 1.
  • Table 1 Development of Staphylococcal 'Epidermides'
  • Example 1 the SOD-like active substance in the culture supernatant of Staphylococcus aureus + Ipidermides was measured.As a result, the experimental group to which zinc sulfate and manganese chloride were added showed higher values than the control group.
  • the harmful pathogen Staphylococcus aureus differs from the useful resident bacterium Staphylococcus epidermides by adding zinc oxide and chloride. No particular promotion of growth was observed with cancer, but rather a tendency toward inhibition.
  • Sample preparation method For sample preparation, culture was performed on a 100 ml flask at the scale of a 50 ml culture solution, and 5 ml was sampled each hour. The culture was immediately centrifuged (10,000 rpm, 4 ° C, 10 minutes) to separate cells and supernatant. Cool the collected supernatant with ice, add acetone at 20 ° C with stirring to a final concentration of 75%, and leave the mixture in ice for 2 hours. Thereafter, the precipitate was collected by centrifugation again (10, OOOrpnu 4 ° C, 10 minutes). Dissolve the precipitate in a small amount of purified water, freeze at 180 ° C and freeze-dry to remove acetate.
  • Protein quantification method Lowry method was used for quantification of protein. .
  • a 0.4 ml sample containing 10 to 100 g of protein is placed in a test tube, and an alkaline copper solution (1 ml of 1% copper sulfate and 1 ml of 2% rossiel salt is mixed with 2% carbonic acid) Sodium, added to 100 ml of 0.1 N sodium hydroxide)
  • Add 0.2 ml of 1 N phenol reagent stir, and leave at room temperature for 30 minutes. Thirty minutes later, colorimetric determination was performed at 750 nm.
  • Bovine serum albumin (BSA, SIGMA) was used as the standard solution.
  • Measuring method of SOD-like active substance Take 50 /] sample in a test tube, dissolve X0D (xanthine oxidase) solution in 0.5M ammonium sulfate, 1 mM EDTA-2Na solution at 20 ° C Dissolve immediately before use, and dilute so that the change in 0D560nm per minute is 0.0185), add 50/1, and keep in a 25 ° C water bath for 10 minutes without stirring. After heating to 25 ° C, solution A (0.
  • Sample Nos. 1 and 2 are manganese / zinc combination and calcium carbonate Sample No. 3 was prepared as a control to examine the irritation properties of Pem. As a result of the judgment by the naked eye, there was no red spot or irritation, and no problem was found in safety.
  • Lipid peroxide was quantified by the TBA (thiobarbituric acid) method shown below.
  • 0.1 ml was taken out from the sample solution, 2.0 ml of TBA reagent (0.2% tiobarbituric acid, 5.0% acetic acid pH3.5) was added, heated at 100 ° C for 60 minutes, and then cooled with water.
  • the final metabolite MDA malonaldehyde
  • the cosmetics of the present invention containing appropriate amounts of the metal ions zinc and manganese, the healthy growth of useful normal flora of skin and the secretion of SOD-like active substances from the cells are promoted, and the growth of skin harmful bacteria It is expected to be effective in preventing skin cells, preventing active oxygen damage to skin cells, and preventing skin cell aging.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une préparation cosmétique contenant des ions de zinc ou de manganèse, ou les deux, qui constituent un ingrédient servant de nourriture à des bactéries utiles propres à la peau de la personne considérée, et qui accélèrent la sécrétion de substances actives agissant comme des SOD obtenus à partir de telles bactéries. Cette préparation est inoffensive pour la peau, ou moins nuisible, et elle a pour effet d'inhiber indirectement son oxydation.
PCT/JP1996/003571 1995-12-05 1996-12-05 Preparation cosmetique WO1997020539A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33989895A JP3608059B2 (ja) 1995-12-05 1995-12-05 化粧料
JP7/339898 1995-12-05

Publications (1)

Publication Number Publication Date
WO1997020539A1 true WO1997020539A1 (fr) 1997-06-12

Family

ID=18331847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1996/003571 WO1997020539A1 (fr) 1995-12-05 1996-12-05 Preparation cosmetique

Country Status (2)

Country Link
JP (1) JP3608059B2 (fr)
WO (1) WO1997020539A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155686A1 (fr) * 2000-05-18 2001-11-21 L'oreal Utilisation du maganèse dans le traitement des rides

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791260B1 (fr) * 1999-03-26 2003-06-06 Dior Christian Parfums Compositions cosmetiques ou dermatologiques contenant au moins une substance destinee a augmenter la fonctionnalite et/ou l'expression des recepteurs membranaires cd44 des cellules de la peau
JP4641150B2 (ja) * 2004-04-20 2011-03-02 伯東株式会社 抗酸化物質分泌促進剤及び抗酸化物質の製造方法
ES2316312B1 (es) * 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
KR101406808B1 (ko) * 2011-11-18 2014-06-12 가부시키가이샤 바이오제노믹스 미용 방법, 스킨케어용 조성물 및 건조 균체

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57134408A (en) * 1981-02-13 1982-08-19 Minato Sangyo Kk Skin activating agent
JPS60174711A (ja) * 1984-02-20 1985-09-09 Kanebo Ltd 日焼け止め化粧料
JPS6339808A (ja) * 1986-08-05 1988-02-20 Risuburan Prod:Kk ミネラル成分含有化粧品用組成物
JPH0597645A (ja) * 1991-10-09 1993-04-20 Riyuuhoudou Seiyaku Kk 化粧料
JPH05285370A (ja) * 1992-04-14 1993-11-02 Kao Corp 撥水・撥油性粉体及びこれを含有する化粧料
JPH07149787A (ja) * 1993-11-29 1995-06-13 Toyo Beauty Kk 収斂・結着性化合物および医療用・化粧用製剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57134408A (en) * 1981-02-13 1982-08-19 Minato Sangyo Kk Skin activating agent
JPS60174711A (ja) * 1984-02-20 1985-09-09 Kanebo Ltd 日焼け止め化粧料
JPS6339808A (ja) * 1986-08-05 1988-02-20 Risuburan Prod:Kk ミネラル成分含有化粧品用組成物
JPH0597645A (ja) * 1991-10-09 1993-04-20 Riyuuhoudou Seiyaku Kk 化粧料
JPH05285370A (ja) * 1992-04-14 1993-11-02 Kao Corp 撥水・撥油性粉体及びこれを含有する化粧料
JPH07149787A (ja) * 1993-11-29 1995-06-13 Toyo Beauty Kk 収斂・結着性化合物および医療用・化粧用製剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155686A1 (fr) * 2000-05-18 2001-11-21 L'oreal Utilisation du maganèse dans le traitement des rides
FR2809005A1 (fr) * 2000-05-18 2001-11-23 Oreal Utilisation du manganese dans le traitement des rides

Also Published As

Publication number Publication date
JPH09157128A (ja) 1997-06-17
JP3608059B2 (ja) 2005-01-05

Similar Documents

Publication Publication Date Title
Duncan et al. Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate
US4259318A (en) Poison ivy relief composition
KR102194315B1 (ko) 락토바실러스 람노서스 균주를 접종하여 발효시킨 병풀 발효 추출물을 포함하는 항산화용 또는 피부 마이크로바이옴 균형 유지용 화장료 조성물
KR102293593B1 (ko) 바다고리풀 추출물을 포함하는 피부 외용제 조성물 및 기능성 식품
JP6868611B2 (ja) スーパーオキシドジスムターゼ（ｓｏｄ）に富むテトラセルミス チュイイ種の微小藻類のバイオマスを得る方法
US20180325969A1 (en) Cosmetic and pharmaceutical applications of lactobacillus pentosus
JP3573941B2 (ja) ヒアルロニダーゼ阻害活性を有する組成物及び該組成物を含有する化粧料
JP5383963B2 (ja) 腐植、腐植抽出液および保湿液、ならびにそれらの製造方法および使用
Sela et al. Inhibition of superoxide production in human polymorphonuclear leukocytes by oral treponemal factors
Grenier Antagonistic effect of oral bacteria towards Treponema denticola
Yoshpe-Purer et al. Factors affecting catalase level and sensitivity to hydrogen peroxide in Escherichia coli
WO1997020539A1 (fr) Preparation cosmetique
Yoon et al. The antimicrobial effect of fluorides (acidulated phosphate, sodium and stannous) on Actinomyces viscosus
KR101020535B1 (ko) 연 발효수로 제조된 화장료 조성물
Biju et al. Formulation and evaluation of an effective pH balanced topical antimicrobial product containing tea tree oil
CN104606097B (zh) 一种具有强效防腐功效的组合物及在化妆品中的应用
CN105796404A (zh) 一种防腐组合物及在日用化学品中的应用
KR100583792B1 (ko) 황토수 및 생약재 추출물을 함유하는 피부미백, 항염증 및항비듬 화장료 조성물
KR102293592B1 (ko) 제주비단망사 추출물을 포함하는 피부 외용제 조성물 및 기능성 식품
US5650149A (en) Cosmetic composition for proliferating indigenous bacteria on skin
JP6253361B2 (ja) 皮膚外用剤
JP3771242B2 (ja) 化粧料
CN109806205B (zh) 一种西青果提取物及其抗菌用途
Moon et al. The intrinsic antimicrobial activity of bamboo salt against Salmonella enteritidis
JP3101090B2 (ja) 皮膚外用剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase